Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency.

Blood - 25 Aug 2016

Lo Bernice, Fritz Jill M, Su Helen C, Uzel Gulbu, Jordan Michael B, Lenardo Michael J

Abstract excerpt

CTLA-4 is a critical inhibitory "checkpoint" molecule of immune activation. Several recent reports have described patients with immune dysregulation and lymphoproliferative disease resulting from 2 different genetic diseases that directly or indirectly cause CTLA-4 deficiency. Numerous articles have also been published describing CTLA-4 blockade in cancer immunotherapy and its side effects, which are ultimately...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Checkpoints
Share to CTLA-4 Antigen
Share to Immune System Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Mutation

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 27418640
DOI: 10.1182/blood-2016-04-712612
PMCID: PMC5000841

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency.PMID 27418640Read ↗

Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes.Semantic proximity Read ↗

Immune Checkpoint Inhibitors to Treat Malignant LymphomasSemantic proximity Read ↗

Increased Risk for Malignancies in 131 Affected CTLA4 Mutation CarriersSemantic proximity Read ↗

Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.Semantic proximity Read ↗

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer TherapeuticsSemantic proximity Read ↗

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious DiseasesSemantic proximity Read ↗

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse eventsSemantic proximity Read ↗

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management.Semantic proximity Read ↗

Immune Checkpoint Molecules-Inherited Variations as Markers for Cancer Risk.Semantic proximity Read ↗

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4Semantic proximity Read ↗

Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4Semantic proximity Read ↗

A Patient with CTLA-4 Haploinsufficiency with Multiple Autoimmune Presentations: A Case Report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.